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Abstract: Understanding and apprehension of the characteristics and circumstances in which mesen-
chymal stem cells (MSCs) affect and make alterations (enhance or reduce) to the growth of tumors 
and metastasis spread is pivotal, not only for reaching the possibility to employ MSCs as drug delivery 
systems, but also for making forward movement in the existing knowledge of involvement of major 
factors (tumor microenvironment, soluble signaling molecules, etc.) in the process of carcinogenesis. This capability is re-
liable because MSCs present a great basis for engineering and constructions of new systems to target cancers, intended to 
secrete therapeutic proteins in the tumor region, or for delivering of oncolytic viruses’ directly at the tumor site (targeted 
chemotherapy with enzyme prodrug conversion or induction of tumor cell apoptosis). MSCs as a crucial segment of the 
tumor surroundings and their confirmed tumor tropism, are assumed to be an open gateway for the design of promising 
drug delivery systems. The presented paper reviews current publications in this fieldwork, searches out the most recent 
patents that were published after 2012 (WO2014066122, US20140017787, WO2015100268, US20150086515), and tries 
to present the current progress and future prospective on the design and development in anti-cancer drug delivery systems 
based on MSCs.  
Keywords: Cancer therapy, cellular therapy, drug delivery, mesenchymal stem cells, oncolytic viruses, pro-drug, target ther-
apy.
INTRODUCTION 
 Despite the prevailing efforts of impressive and long last-
ing attempts to create improvements in actions designed to 
achieve advances in therapy and methods for treating cancer, 
the long-established and classic therapies as radiotherapy and 
chemotherapy are still on the first line to control cancer. 
Several types of cancers do not response to ordinary used 
medical treatments. In the past, the main efforts and research 
in this field were focused only on cancer cells entity. Except 
malignant epithelial cells that have prime importance in cancer 
formation, the surrounding components or microenvironment 
consisted of diverse cell types; the extracellular medium and 
specific signaling molecules have a significant impact as 
well [1-3]. A selection of previously mentioned elements and 
their combination is crucial for cancer spread.  
 The transportation and distribution of drugs against can-
cer exactly to the tumor site even now is a great provocation 
in the plan of action to design effective cancer treatment. 
Mesenchymal stem cells (MSCs) as a crucial segment of the 
tumor surroundings and their confirmed tumor tropism, as-
sume to be an open gateway for the design of promising drug 
delivery systems. Friedenstein et al. for the first time describe 
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MSCs as multi-potent mesenchymal stromal cells, very simi-
lar to fibroblasts and located in the bone marrow [4]. De-
pending on their morphology, MSCs are a heterogeneous 
population of cells and their characterization (description and 
recognition) is based on a combination of criteria as adher-
ence to plastic, expression of CD73, CD90 and CD105, lack 
of haematopoietic cell markers such as CD34, CD45, CD19, 
CD11b, HLA-DR on the cell surface and the potential for 
multi-differentiation into osteoblasts, adipocytes and chon-
droblasts in vitro. Multipotent MSCs can be successfully iso-
lated from human bone marrow, adipose tissue and Wharton’s 
Jelly of umbilical cord [5, 6]. Several studies have docu-
mented that MSCs derived from fetal tissue have more advan-
tages than MSCs derived from adult tissue, as they can be 
isolated noninvasively and without ethical reservations and 
they possess active tumor-homing capacity [7]. From a large 
number of members in the stem cells class, MSCs are the 
first type to be employed in clinical practice, particularly in 
regenerative medicine and tissue engineering field, mainly in 
view of the fact that they possess the ability for large-scale 
proliferation, self-regeneration, multipotent differentiation and 
suitability for autologous transplantation. In this view, thera-
peutically advantageous features of MSCs are existing possi-
bilities for easy isolation and acquisition, fast expansion in 
culture, feasibility of autologous transplantation and their 
significant paracrine effects [5, 6, 8-10]. In the course of the 
proliferation and differentiation processes, MSCs cooperate 
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with other cells both through cell-cell interactions and paracrine 
signalizations (growth factors, cytokines, antifibrotic or an-
giogenic mediators) [11]. There are discrepancies in the re-
ported data about the self-renewal ability of MSCs, that is, 
the ability to undergo numerous cell divisions while retain-
ing their stem cell identity. This might be partially explained 
by the presence in tissues of diverse precursor types, hetero-
geneous in nature and origin of cells (that seem similar ac-
cording to their in vitro characteristics) [12]. 
 First-line targets for MSCs are sections of new stroma 
formation where the site of hematopoiesis, inflammation, 
and/or injury belongs. Because of this property, MSCs can 
contribute to reparative processes in different pathological 
conditions, including cancer. Since the tumor-homing capacity 
of MSCs was discovered, the application of specific gene-
engineered MSCs has held great potential for anticancer 
therapies. Accumulation and persistence of MSCs in solid 
tumors have been reported [13-17] and also demonstrated in 
experiments with a number of human cancer cell lines [2, 18-
23]. This anticancer dual-targeted strategy is based on MSCs’ 
capacity of tumor-directed migration and in situ expression 
of tumor-specific anticancer genes. 
 MSCs provided by exogenous sources also have prefer-
ences to accumulate and integrate into the tumor tissue. This 
important feature is shown in in vivo experiments with tu-
mor-bearing animal models. The assembly of molecules se-
creted by tumors, as for example monocyte chemotactic pro-
tein-1 secreted by primary breast tumors [24], stimulates the 
migration of MSCs and is liable for functional response with 
different classes of receptors located on the MSCs surface 
[17, 24, 25]. This directed migration and specific incorpora-
tion of MSCs at tumor target site was observed in studies 
with cell cultures in vitro and animal models in vivo. Those 
tumor tropism abilities are consistent, and also independent 
of cancer type and delivery route of MSCs. All these charac-
teristics of MSCs are suggested as a tool which gives good 
grounds for delivering various biological agents with the 
expectance of great potential for anti-cancer therapy [23, 26]. 
Concerning, at some points, the inconsistent and conflicting 
results about MSCs function in tumor microenvironment, the 
effects over inhibition and/or stimulation, and the prolifera-
tion of cancer cells obtained from several studies, there are 
still some scientific disagreements. In general, results leading 
to the proposal of two major elements are likely to be corre-
lated with the significant impact on cancer development. The 
first element is bidirectional cell communication, and the 
second one is the possibility of suppressive outcomes over 
the immune system which at the same time make tumor 
genesis possible [16, 27-29]. Almost certainly, this bidirec-
tional cellular communication is a crucial stage in tumor 
progression (Fig. 1). 
MSCs ENGINEERED AS ANTICANCER DRUG DE-
LIVERY SYSTEMS 
 Concerning the persisting option for carrying therapeutic 
agents straight at the targeted tumor by the application of 
MSCs as carriers and consequently secure raised concentra-
tions of these agents locally [30], there are many research 
groups working on different aspects of the possibility to in-
volve these cells as drug delivering systems for therapeutic 
proteins, replicative oncolytic viruses, or for enzyme prodrug 
conversion (Table 1). Therapeutic proteins which raised great 
interest because of the possibility to be managed by MSCs are 
interferon  (IFN) [31, 32] and  (IFN) [23, 31-34], inter-
leukin (IL) 12 [35], cytokine IL2 [36] and chemokine CX3CL1 
(fractalkine) [37].  
Fig. (1). Bidirectional cellular communication among MSCs and tumor cells. 
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 There are a number of studies of effects of IFN and 
IFN incorporated into systems delivered by MSCs over 
tumor growth showing the inhibitory effect of IFN and its 
usefulness as adjuvant therapy for the elimination of micro-
metastasis in risk patients [38], while anticancer effect of 
IFN is determined as apoptosis-stimulation effect [39, 40] 
and only toxicity observed after its systemic administration 
limits its clinical applications [41]. This undesired effect of 
IFN can be reduced by using MSCs as carriers for targeted 
delivery. One study by Ren et al., 2008 [32] is representative 
where mouse MSCs genetically engineered to express human 
IFN coding sequence in prostate cancer model are used. 
 IL-12 (a heterodimeric glycoprotein) [35, 42, 43] or IL-2 
[36, 44] secreted by MSCs initiates an immunoreaction and 
stimulates infiltration of inflammatory cells at the tumor site, 
which is a way to avoid systemic toxicity at the same time 
[45]. There is a study performed by Chen et al. in 2006, 
where genetically modified MSCs for secretion of IL-12 of 
mouse origin were evaluated according to their anti-cancer 
potential in three types of tumor models in experimental 
animals [35]. In a similar study, Stagg et al. [44] showed that 
in the case of melanoma cancer model investigated, when 
MSCs producing IL-2 are mixed with B16 cells, delayed 
tumor growth is achieved in 90 % of examined cases. 
 Different molecules can be a target site for antiangio-
genic therapy due to their engagement in tumor-mediated 
angiogenesis [46] which gives possibility for use of MSCs 
expressing antiangiogenic factors (thrombospondin (TSP)-1) 
to inhibited tumor development [47-49].  
 One way of modification of MSCs is the possibility of 
releasing conditional replicative oncolytic viruses [50-53]. 
When oncolytic viruses are systemically delivered, the host 
immune system is responsible for the defense, which results 
in the elimination of the circulating viruses before they can 
reach the tumor site. Autologous MSCs are not recognized as 
foreign by the host immune system, and those incorporated 
oncolytic viruses can reach the tumor without systemic limi-
tations [54]. The most extensively used one is the oncolytic 
virus Adenovirus serotype 5 (Ad5). The disadvantage of its 
use is the need for internalization into host cells [55]. An-
other virus with broad application where engineered MSCs 
act as carriers is Herpes simplex virus type 1 (HSV-1). To 
control Ad5’s limitations, modifications of adenoviruses 
have been researched with great attention put on chemical 
conjugation [56], fiber-modification of adenoviruses [57], 
etc. Lately, Menotti et al., have investigated possible modifi-
cations and designed HER2 (human epidermal growth factor 
receptor 2)-retargeted HSV-1 vectors by using the process of 
conjugation with a single-chain antibody (scFv) [58]. Addi-
tional investigations for new carriers of oncolytic viruses are 
still going on. 
 MSCs are used as vehicles for targeted anticancer therapy 
by using the mechanism of enzyme prodrug conversion [59-
64]. The basic of this mechanism is the conversion of a pro-
drug (which has low toxicity) to a high toxic metabolite (pro-
duced only at tumor site) where the reaction is catalyzed by 
enzymes [65, 66]. In this way systemic toxicity of chemother-
apy is kept on minimum because the concentration of the drug 
in blood is on the possible lowest level [67]. Generally, the 
most applicable system is the cytosine deaminase (CD)-5-
fluorocytosine (5-FC) (enzyme CD converts the relatively less 
toxic prodrug 5-FC to toxic metabolite 5-fluorouracil (5-FU)).  
 In experiments with MSCs expressing tumor necrosis 
factor-related apoptosis inducing ligand (TRAIL) (a type II 
membrane ligand from Tumor Necrosis Factor (TNF) fam-
ily) anticancer effects are also detected, probably by induc-
tion of apoptosis [68-74]. This effect was reported in case of 
prostate cancer investigated [19], and also in other experi-
mental cancer models (glioma and lung cancer). How tumor-
tropic capability of MSCs is adjunct by the engineering 
process remains largely unknown and investigations are still 
going on. 
RECENTLY PUBLISHED PATENTS (2012-PRESENT) 
CONCERNING MSCs AS DELIVERY VEHICLES 
FOR ANTICANCER DRUGS 
 The results and conclusions throughout the investigations 
about the relationships MSCs-tumor cells obtained from sci-
Table 1. MSCs used as Drug Delivery Vehicles for Anticancer Agents. 
Anticancer Agent that can be Delivered Cancer Model Investigated Cited References 
Interferon   Glioma, cancer of prostate, lung and pancreatic tumors  [23, 31-34, 38]  
Interferon   Melanoma lung metastasis model  [32, 41]  
 Interleukin 12  Lung and breast cancer models [35, 42, 43]  
Interleukin 2  Glioma  [36, 44]  
Chemokine CX3CL1  Metastatic cancer model [37]  
Antiangiogenic agents Glioma  [47-49]  
Oncolytic virus  Lung and breast tumor, metastatic cancer model [50, 52-54]  
Cytoreagents for gene therapy and targeted chemotherapy  
Melanoma (mouse), glioblastoma cells (human), pancreatic 
carcinoma, colon tumors  
[59-64, 67]  
Tumor necrosis factor-related apoptosis inducing ligand Brain tumors, lung cancer, glioma, metastatic cancer model [19, 70-72] 
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entific research are not consistent, and there are multiple 
factors proposed to have contributed to this. Maybe the het-
erogeneity between MSC populations is one of the prime 
factors that must be taken into consideration. The recently 
published patents reviewed in the presented manuscript, in 
general, proposed MSCs as promising new drug delivery 
systems.  
 Pittenger and Aggarwal are the authors who, in a patent 
published in 2011, demonstrate various applications of 
MSCs and their interactions with dendritic cells (DC1 and 
DC2), effector T-cells (Th1 and Th2), and NK cells [75]. 
The authors find that MSCs stimulate DCs to produce IFN,
which promotes tumor suppression. The same authors con-
tinued their work and in 2014 published another invention 
which is an updated version of the previous one [76] (Table 
2). 
 In a recently published patent in 2013, Crawford and 
Southgate [77] also described uses of multi-potent stem cell. 
In this invention, methods for purification of stem cells 
population from synovial fluid and blood are provided. 
These cells are embryonic in character, and in contrast to 
other adults stem cells (which require a longer period of cul-
ture before expression), express key embryonic transcription 
factors within a few days of isolation. These cells can prolif-
erate and differentiate into all three germ layers (mesoderm, 
ectoderm and endoderm). In another aspect, the invention 
provides methods for forming adipocytes, muscle cells, neu-
ral cells, hepatocytes, endothelial cells, and hematopoietic 
cells. Methods of treatment of different diseases or condi-
tions are also given. In the patent also published in 2013 by 
Brodie and Slavin, in vitro modeling of MSCs and cell-based 
therapy of human brain diseases are given [78]. 
 More recently, in 2014, Peled and Steinhardt’s patent 
[79] was published also concerning methods of culturing and 
expanding MSCs. The novelty in the presented method is 
culturing a population of the MSCs in a medium where the 
aryl hydrocarbon receptor antagonist is included. Another 
similar research is the patent published by Sabbadini in 
2013, where direct inhibitors of lysophosphatidic acid (LPA) 
are used as a component in the system for stem cell therapy 
[80]. Very recently, in 2015, in the patent published by Lim 
and Lye [81], a method of deriving MSCs is also described. 
In contrast to methods previously used, this new method 
provides a clinically relevant and reproducible protocol for 
isolating similar or homogenous MSCs populations from 
differentiating embryonic stem cell (ESC) colony into cells. 
In order to obtain MSCs, the ESCs are propagated in a serum 
free medium containing fibroblast growth factor 2. The nov-
elty of the presented protocol is that serum, mouse cells and 
genetic manipulations are not required, manipulations per-
formed require less time and the protocol is highly scalable.  
 In a patent published in 2012, the author presented re-
lated therapies where the application of MSCs is an option 
[82]. Research is focused on the invention of a method 
whose application will avoid troubleshooting occurring in 
stem cell therapy in adult patients where contradictions about 
the prediction of the behavior of transplanted stem cells in a 
patient’s body are still existing. The prime issue in the pro-
posed method is the incubation of isolated MSCs with Toll-
like receptor ligand (TLR). With in vitro studies on human 
cancer cell lines the divergent effects of MSC1 (stimulated) 
and MSC2 (non-stimulated) are shown. The author of the 
above mentioned patent, Betancourt, A.M., in 2014 pub-
lished another patent extension of the first one, where TLR 
ligand is selected from aminoalkyl glucosaminide-4-phosphates, 
interferons, TNF, GM-CSF, lipopolysaccharide (LPS), or 
combinations thereof [83]. TNF (formerly referred as TNF-
alpha), as a strategy for treating tumors, is a point of interest 
in the invention published by Cheng et al. [84]. TNF is a 
cytokine with well-known anticancer properties and is used 
as an agent for solid tumors treatment. The authors provided 
a method for using engineered MSC as a vehicle for deliver-
ing secreted tissue necrosis factor-RGD4C fusion polypep-
tides for reducing side effects of TNF (fever and decreased 
blood pressure) before therapeutic doses can be reached. In 
addition, to monitor the localization and viability of the en-
gineered MSCs in vivo after administration in animal-
recipient, a lentiviral vector was constructed with dual re-
porter gene mrfp-ttk included in it. Genetically modified 
MSCs can include a nucleic acid sequence operably linked to 
a gene expression promoter and encoding the heterologous 
fusion polypeptide, which includes a tissue necrotic factor 
region and an integrin-binding region. An additional part of 
this work is a method for modulation of the proliferation of 
target tumor cells by a delivered population of MSCs. The 
step of monitoring the distribution of the genetically modi-
fied MSCs in the recipient (animal or human) can be de-
tected by bioluminescence, fluorescence, MRI, or PET scan-
ning [84]. The interest for TNF is continuously present and 
one very recently published invention also describes the use 
of this cytokine [85]. The invention presents genetically en-
gineered MSCs as a vehicle for delivering tissue necrosis 
factor-RGD4C fusion polypeptides intended for cancer 
treatment. This strategy reduces the side effects of TNF. 
 Methods of generating and expanding the human embry-
onic-mesenchymal stem cells (hES-MSCs) are given in two 
patents of Wang and Xu, just recently published [86]. These 
cells are useful for the prevention and treatment of T cells 
related autoimmune disease, as well as for delivering agents 
across blood-brain and blood-spinal cord barrier. The hES-
MSCs may be in the form of a single cell, cell culture, a so-
lution or a pharmaceutical preparation. The agent included in 
it is for the treatment, prevention or diagnosis of a disease or 
injury and can be, but is not limited to drugs, proteins, DNA, 
RNA, and small molecules. In one embodiment, a kit com-
prises hES-MSCs and cell delivery carriers are provided. In 
the second patent, in addition, conditions for the develop-
ment of embryonic stem cells through an intermediate differ-
entiation of trophoblasts and differentiation of trophoblasts 
into the hES-T-MSCs are given (Table 2). Solutions and 
pharmaceutical preparations which include hES-T-MSCs, 
methods of making the hES-T-MSCs and their uses are also 
given.  
 Methods for diagnosis, prevention, treatment, or monitor-
ing of brain tumors are given in the patent from 2013 of 
Chang et al. [87]. The patent relates to a gene therapy com-
position for transferring a therapeutic gene, a marker gene, or 
their products to the cells expressing IL-8 or growth-
regulated protein alpha (GRO-) and it induces tropism of 
Umbilical Cord Blood-Derived Mesenchymal Stem Cells 
(UCB-MSCs). UCB-MSCs are genetically modified to trans-
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fer a therapeutic agent inhibiting brain tumor cells growth or 
a therapeutic gene (an antitumor gene, a prodrug converting 
enzyme gene, or oncolytic virus), or a product of it. An im-
portant embodiment of the presented patent is the composi-
tion of a kit for treating brain tumors where the expression 
vector of a prodrug converting enzyme gene, UCB-MSCs 
and a prodrug anticancer drug are included. The prodrug 
converting enzyme gene can be selected from a cytosine 
deaminase gene and a CYP2B1 gene. Also, a separate em-
bodiment of the same patent is the composition for diagnos-
tic or monitoring of brain tumors treatment which includes 
UCB-MSCs, labeled with a detectable marker. A marker can 
be selected between luciferase-containing enzyme-based 
fluorescent detector or Tat peptide-derivatized magnetic 
nanoparticles. The same approach, application of magnetic 
nanoparticles for labeling MSCs, is also an object of interest 
in another invention [88] where a recently developed method 
that exploit MRI to follow MSCs labeled with iron oxide 
nanoparticles is presented. The use of iron oxide labeled-
MSCs is encouraged for the target delivery of anticancer 
agents and also for the possibility to damage tumor cells by 
persistent option for thermotherapy. The above mentioned 
authors, Chang et al. [87], in the context of the use of UCB-
MSC, again in 2013 studied stem cells having an effective 
tropism for tumors and published another patent related to a 
pharmaceutical composition comprising UCB-MSC. In this 
composition the UCB-MSC functions as a carrier for gene 
therapy (prevention and treating) for brain tumors [89]. The 
inventors performed an experiment with introducing a gene 
coding green fluorescent protein (GFP) into UCB-MSCs. 
According to the presented invention, a pharmaceutical 
composition (kit) containing UCB-MSC can be used to diag-
nose, prevent, and treat diseases related to cells expressing 
IL-8 or GRO- or brain tumors. Many research groups as 
their focus of interest have cancer vaccines and their capabil-
ity to target tumors and make differences between neoplastic 
and healthy cells [90, 91]. In an invention just lately pub-
lished, in 2014, cancer vaccines are proposed to be used to-
gether with chemotherapy, for example [92] (Table 2). 
 As different epigenetic (cell proliferation, inhibition of 
apoptosis and induction of angiogenesis) and genetic (activa-
tion of oncogenes and inactivation of tumor-suppressor 
genes) factors can be involved in cancer initiation, in an in-
vention published in 2013 by Cohen, pharmaceutical compo-
sitions and methods for treatment of cancer or other prolif-
erative diseases are evaluated [93]. The prime position in the 
invention is taken by intra- and extracellular components of 
stem cells, which can be a rich source of biomolecules asso-
ciated with epigenetic reprogramming, or alteration of the 
malignant nature of the cancer cells.  
 Similarly, the recent published invention of Habib and 
Gordon [94] provides an apoptosis-modulating cell-free 
composition which is the extracellular medium of a stem cell 
and therapeutic uses thereof. The inventors examined a cer-
tain class of stem cells, known as “OmniCytes”, which could 
be used as vehicles for delivering drugs to cancer cells. Can-
cer cell lines were treated with a pro-apoptotic agent such as 
staurosporine, cisplatin or paclitaxel and cultured with Om-
niCytes. When an experiment was made with Transwell sys-
tem (allows the exchange of soluble factors, but prevents 
cell-cell contact), the effect was secretion of one or more 
factor(s) from OmniCytes that potentiated the effect of the 
pro-apoptotic agent. This apoptosis-modulating factor was 
proposed for use in therapeutic applications of hyperprolif-
erative disorders, particularly cancer. When non-cancerous 
cells were exposed to a pro-apoptotic agent and OmniCytes 
in a Transwell assay, the secreted factor had a protective 
effect, reducing the number of cells which underwent apop-
tosis. The protective effect on non-cancerous cells is a par-
ticularly useful part of this invention, because in the treat-
ment of cancer healthy cells will be spared. It is likely that 
other types of stem cells, such as HSCs and MSCs, can also 
excrete the factor and are suitable types of stem cells from 
which the factor(s) may be isolated and used to prepare a 
conditioned extracellular medium [94]. Similar to patents 
described above one type of intra- or extracellular compo-
nents of stem cells, particles, which may comprise a vesicle 
or an exosome secreted by MSCs are used in a patent pub-
lished in 2015 [95]. The authors show that these particles 
possess biological properties of a MSC and they proposed 
the use of conditioned medium containing them for possible: 
1) cardioprotection effect and 2) treatment of a group of dis-
eases as bone marrow disease, skin disease, degenerative 
disease and cancer. 
 Suicide genes have become known as an attractive alter-
native therapy for the treatment of different resistant and 
complex cancer types. Suicide genes from non-human 
sources have emerged as an attractive approach to the treat-
ment of brain tumors. MSCs expressing a suicide gene show 
excellent and highly selective anticancer effects (conversion 
of a prodrug to an anticancer agent at the cancer site) as in 
the case of CD as suicide gene which converts 5-FC to cyto-
toxic 5-FU killing neighboring cells (bystander effect). 5-FU 
itself is cytotoxic when it is directly administrated. But, 
when a combination of a suicidal gene and prodrug of 5-FU, 
namely 5-FC is administered, 5-FU is produced selectively at 
tumor cells [96, 97]. This possibility presented in the work of 
Chang et al., 2010 [98] is explained as being applicable on 
humans, ex vivo therapeutic modality, wherein by using bac-
terial CD-expressing MSCs, the recurrence of malignant 
brain tumors can be effectively suppressed. Several preclini-
cal parameters, critical for this therapy, including the total 
CD activity and 5-FC concentration, are assessed in this 
study. 
 Another standard model for use of a suicide gene is her-
pes simplex type 1 thymidine kinase (HSVTK), which con-
verts non-toxic gancyclovir into a toxic metabolite [59]. By-
stander effects were observed after intratumoral administra-
tion of MSCs and intraperitoneal injection of gancyclovir, 
with a significant fraction of mouse model animals surviving 
long-term period [99]. A novel and worth mentioning aspect 
of this study was the use of imaging techniques PET and 
MRI to track the injected cells and the possibility of deter-
minate the therapeutic efficacy. The translation of this thera-
peutic strategy to clinic practice may be questionable, but 
there is no doubt about the usefulness of developing molecu-
lar imaging techniques to track cells in vivo.
 The same suicide gene, as indicated above, is used in the 
patent published in 2012 by Nelson, which provides a 
method for treatment of pancreatic cancer through i.v. 
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Table 2. Patents Concerning MSCs and their Use as Anticancer Drug Delivery Systems (Published 2012-Recent). 
Patent/Year Inventor(s) Reference Description of the Invention 
WO2012051210 (2012)  Betancourt, A.M.  [82]  MSCs and related therapies  
US20120010499 (2012)  Janes, S.M., Lythgoe, M.F., Pankhurst, Q. [88]  Uses of MSCs incorporated with nanoparticles for cancer treatment 
US20120087901 (2012)  Nelson, P.  [100]  Engineered MSCs and methods of using them to treat tumors 
WO2012071527 (2012) Boyan, B.D., Schwartz, Z., Lee, C.S.D., 
Leslie, S.K., Kinney, R.C. 
[104] 
Protein delivery from stem cell microcarriers 
US20120263685 (2012) 
Ra, J.C., Kang, S.K., Woo, S.K., Youn, H.Y., 
Lee, H.W., Seo, K.W. 
[107] 
hASCs as anti-tumor composition 
WO2012106281 (2012) Shah, K. [114] Multimodal TRAIL molecules 
US8574567B2 (2013) Crawford, K.D., Southgate, C. [77] Uses of multipotent stem cell 
WO2013124815 (2013) Brodie, C., Slavin, S. [78] MSCs for in vitro modeling 
WO2013023040 (2013)  Sabbadini, R.A.  [80]  Stem cell therapy using inhibitors of LPA  
WO2013158962 (2013) Cheng, Z., Chen, K., Chen, X. [84] MSCs as delivery toll for TNF and imaging-aided gene therapy 
US20130189189 (2013) 
Chang, J.W., Kim, D.S., Yang, Y-S., Oh, W. [87] Using UCB-MSCs for diagnosis, prevention, or treatment of 
brain tumors 
US8506948B2 (2013) Chang, J.W., Kim, D.S., Yang, Y-S., Oh, W. [89] Using UCB-MSCs for diagnosis, prevention, or treatment 
US20130052272 (2013)  Cohen, S.  [93]  Uses of cell extracts for treatment and prevention of cancer  
US20130171115 (2013) Li, G., Lee, Y.W., Lau, P.Y. [101] Cell-mediated gene therapy using MSCs expressing a suicide gene 
WO2013106774 (2013) Orrichio, E., Wendel, H-G. [102] Cancer-specific suicide gene 
US2014016776 (2014) Aggarwal, S., Pittenger, M.F., Varney, T. [76] Uses of MSCs 
US20140017787 (2014) Betancourt, A.M. [83] MSCs and related therapies 
WO2014011407 (2014) Wang, X., Xu, R-H. [86] Uses of hES-MSC 
WO2014011881 (2014) Wang, X., Xu, R-H. [86] Uses of hES-T-MSC 
US20140056909 (2014) Markovic, S.N. [92] Cancer treatment 
US8652846 (2014) Habib, N.A., Gordon, M. [94] Stem cells derived medium as a pharmaceutical composition 
WO2014066122 (2014) 
Prockop, D.J., Lee, R.H., Yoon, N., Reneau, 
J., Berkowitz, B.A. 
[108] 
Activated MSCs for tumor treatment 
US20140086907 (2014) The General Hospital Corporation [115] Multimodal TRAIL molecules 
US20140369979 (2014) 
Sung, Y.C., Kim, S.W., Kim, S.J., Park, S.H. [116] TRAIL and HSV-TK suicide genes, and anticancer stem cell 
therapeutic agent 
WO2015089280 (2015) Shah, K. [117] MSCs delivered oHSV and TRAIL-oHSV 
US20150197725 (2015) Lim, S.K., Lye, E. [81] Method for deriving MSCs 
WO2015100268 (2015) Chang, A., Nolta, J. [118] Engineered MSCs for secretion of antibody-like molecules 
US20150190430 (2015) Lim, S.K. [95] MSCs particles 
US20150086515 (2015) Cheng, Z., Chen, K., Chen, X. [85] MSCs delivering tissue necrosis factor-RGD4C fusion polypeptides
injected engineered MSCs (CD34- modified cells) [100]. In 
2013, Li et al. published their invention concerning cell-
mediated gene therapy for cancer using MSCs transfected 
also with a suicide gene [101]. The method has a few steps: 
1) introducing a population of MSCs (expressing a suicide 
gene) into the subject; 2) allowing enough time for the mi-
gration of MSCs from the site of administration to the site of 
the tumor; and 3) introducing a prodrug which will be con-
verted to toxic drug, lethal for tumor cells. A prototype sui-
cide gene is thymidine kinase, and the prodrug is gancy-
clovir. Possibilities of using other models of suicide genes 
(CD, purine nucleoside phosphorylase (PNP), cytochrome 
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p450 enzymes (CYP), carboxypeptidases, etc.) and prodrugs 
(5-FC, 6-methylpurine deoxyriboside (MEP), fludarabine 
(FAMP), cyclophosphamide, methotrexate -peptides, etc.) 
are also given. The invention also provides a kit formulation 
for treating a tumor. The improvements given in this patent 
are well-characterized stem cell properties, tumor tropism, 
low immunogenicity, and proliferative capacity suitable for 
bulk production. Another model of suicide gene used in gene 
therapies of cancer is specified in a patent also from 2013, 
published by Orrichio and Wendel [102]. They provide a 
method for using pluripotent and multipotent stem cells that 
have be modified to include an inducible cancer-specific 
suicide gene that selectively kills stem- or progenitor cells 
derived cancerous cells with no effect on other noncancerous 
cells.  
 In a great number of experiments, adenoviruses and their 
modified versions (incorporation of different amino acid 
sections) were used as delivery vectors of viral load specific 
to the tumor site [50-53, 103]. One of the difficulties in the 
treatment of conditions such as cancer is the need to deliver 
large quantities of the therapeutic agent for extended periods 
of time. Boyan et al., in the invention published in 2012, 
present an approach of using MSCs as micro carriers for 
protein delivery [104].  
 MSCs have the property to integrate into the tumor 
stroma which gives them the possibility to deliver a neces-
sary dose of biological agents with short half-life or well-
known toxicity [23]. One of the first studies in this field is 
the patent published by Studeny et al. [105] where MSCs or 
stromal cell precursors are genetically modified to produce a 
therapeutic agent (IFN, IFN or similar). Implementation 
of MSCs expressing IFN results in decreased tumor mass 
and prolonged animal survival (shown in tumor-bearing ex-
perimental animals). Regional secretion of IFN is preferred 
because it decreases systemic toxicity [33]. This regional 
secretion is also preferred for a therapeutic effect of IL-12 or 
IL-2 where an immunoresponse and stimulation of infiltra-
tion of inflammatory cells at the tumor site are observed [36, 
42-44]. The aim of the investigation of Von Laer and 
Heimann, 2011 [106] was to develop a highly potent onco-
lytic viral gene transfer system for therapeutic genes for 
therapy of highly malignant brain tumors (as gliomas) and 
different types of solid tumors. Vesicular stomatitis virus 
(VSV) pseudotype vector is used for gene coding for a gly-
coprotein (GP) of the lymphocyte choriomeningitis virus 
(LCMV). VSV-LCMV-GP pseudotype vector includes at 
least one therapeutical transgene which can be a suicide gene 
(HSV-TK, CD, FKBP-caspase-9) or an immunostimulatory 
gene (encoding IL-2, IL-4, IL-12, etc.) and a virus producing 
cell produces a VSV virion pseudotyped with LCMV-GP. 
The virus producing cell is an adult stem cell, for example 
MSC. The subject of the invention is also the use of VSV-
LCMV-GP system for the preparation of a pharmaceutical 
composition for solid tumors therapy. 
 The work of Ra et al., 2012 [107] is directed at prevent-
ing cancer (providing anticancer activity) by using adult 
stem cells to activate the immune system. This adult stem 
cell may be derived from adipose tissue or epithelial tissue, 
and preferably MSCs are used. These cells secrete specific 
cytokines that activate the immune system and show the 
treating cancer effect by inhibition of the expression of can-
cer cells chemokines. The pharmaceutical composition of the 
presented invention is administered in a therapeutically ef-
fective amount at the early stage of the cancer diseases, if 
possible. 
 Prockop et al., 2014 [108] in their experimental work 
tested the hypothesis that activated human MSCs (hMSCs) 
are tumor suppressive because of the fact that hMSCs acti-
vated with TNF- expressed both TRAIL and Dickkopf-
related protein 3 (DKK-3). It was observed that DKK-3 ex-
pression was increased upon exposure of hMSCs to TNF-
in animal tumor models. The applicants of the patent discov-
ered that the activated MSCs express increased amount of 
agents that inhibit, prevent, or destroy the tumor growth and 
furthermore, that cross-talk between activated MSCs further 
increased the expression of TRAIL and DKK-3. The acti-
vated MSCs can be administered in the amount from 103 to 
109 cells depending on age, weight, and sex of the patient, 
the type and location of the tumor being targeted, in conjunc-
tion with an acceptable pharmaceutical carrier, and in com-
bination with at least one chemotherapeutic agent (doxorubi-
cin, cisplatin, 5-FU, irinotecan, etc.).  
 MSCs secreting TRAIL have been tested in different 
models of cancers in vivo, resulting in notable anti-tumor 
effects [19, 68, 71, 72, 88, 109]. Contrary to previously said, 
MSCs (similar to most other healthy cells) are unsusceptible 
to TRAIL-induced apoptosis [71]. In addition to this, in the 
TRAIL transfected adult MSCs, fetal-MSCs and umbilical 
cord matrix stem cells, there are almost undetectable levels of 
apoptotic pathway components (caspase-8 and caspase-9) 
[110]. The application of this system (MSCs secreting 
TRAIL) has advantages over some of the other engineered 
MSC-delivery systems since there are almost no-detectable 
effects on non-cancerous tissues. Promising early results are 
obtained not only from the investigations with animal models, 
but also from clinical trials carried out currently [111-114].  
 In the patent published by Shah in 2012, the methods of 
implantation of therapeutically engineered MSC with anti-
tumor agents directly into tumor sites after surgery was pre-
sented. MSC-TRAIL cytotoxic therapy showed highly effec-
tive results in inducing apoptosis and potent inhibition of 
brain tumor growth. It was advised that the TRAIL approach 
would significantly improve treatment outcomes [114]. In 
the invention published in 2014 [115] there is description of 
novel compositions comprising multimodal TRAIL agents 
and cells engineered to express such multimodal TRAIL 
agents. These cells can be encapsulated in a scaffold or ma-
trix, and used in the treatment of disorders such as cancer. 
The multimodal therapeutic agents, such as multimodal 
TRAIL agents, are useful in combinatorial therapies with 
chemotherapy, radiotherapy, or surgical interventions. The 
activation of cell surface receptors, such as death receptors 
(DRs), by the multimodal therapeutic agents and cells ex-
pressing such agents (engineered stem cells), represents an 
attractive therapeutic strategy to promote apoptosis of tumor 
cells. The stem cells of interest for use with the compositions 
and methods comprising multimodal TRAIL agents de-
scribed in the invention can be naturally occurring stem cells 
or “induced” stem cells. Stem cells can be obtained or gener-
ated from any mammalian species, including humans. In 
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some embodiments of the compositions and methods de-
scribed, a pharmaceutically acceptable composition for ad-
ministration into a subject comprising a neural stem cell (but 
not limited only to this type of stem cells) and a multimodal 
TRAIL agent is given. Other vectors (herpes simplex virus 
vectors, SV 40 vectors, polyoma virus vectors, papilloma virus 
vectors, etc.) encoding a multimodal TRAIL agent are also 
proposed for usage. For example, there is an embodiment in 
the patent that describes stem cells engineered to produce the 
secreted multimodal TRAIL agents which can be administered 
intravenously and are expected to reach desired areas of the 
brain, such as the site of a glioblastoma [115]. A very new 
invention, also published in 2014, presents DNA cassette en-
compassing a nucleotide sequence encoding TRAIL, a suicide 
gene nucleotide sequence, a recombinant adenovirus, and a 
host cell (preferably stem cell) transduced with the recombi-
nant adenovirus. This work gives a composition for treating 
cancer comprising the host cell and steps of administering this 
composition to a subject [116]. 
 Concerning the possibilities for using genetically engi-
neered MSCs with different properties (secretion of TRAIL, 
delivery of oncolytic viruses, delivery of biological agents, 
etc) it can be noted that in few very new inventions pub-
lished just recently, in 2015, there are efforts to use combina-
tions of above mentioned methods. The patent of Shah [117] 
describes the therapeutic efficacy of MSCs loaded with in-
fectious oncolytic herpes simplex virus (oHSV) and its pro-
apoptotic variant (oHSV-TRAIL). In vitro and in vivo mouse 
glioblastoma multiforme (GBM) model was used. It was 
found that this model mimics exactly the clinic scenario of 
GBM resection and efficacy of MSCs loaded with oHSV and 
variants of it are on site. The result was the induction of 
apoptosis in TRAIL and oHSV resistant GBM and increas-
ing of mice survival. Other also very new approach for tar-
geted cancer therapy is published in 2015 by inventors 
Chang and Nolta [118]. In this invention, the authors harness 
the intrinsic ability of MSCs to home into cancer cells and 
subsequently regulate the secretion of an antibody-like mole-
cule (under a promoter regulation). The invention provides 
an isolated polynucleotide composed of: promoter of expres-
sion of the C-C motif ligand 5 (CCL5 promoter) operatively 
linked to a polynucleotide encoding Fc and hinge region of a 
human IgG CD44 variant 6 (CD44v6). These engineered 
MSCs for secretion of antibody-like molecules that specifi-
cally target the metastatic cancer variant CD44v6, because of 
controlled expression of the CCL5 promoter, are effectively 
able to initiate immune cells reaction and the complement 
cascade. Because cancer cells attract these engineered MSCs 
with specific action, metastatic process of cancer stem cells 
can be disrupted, which can lead to elimination of early can-
cer cell metastasis. 
 Table 2 summarizes recently published (2012-present) 
inventions related to this subject and presented in this paper. 
The different roles of MSCs in anticancer drug delivery  
systems with their key points are noted and summarized in 
Table 3.
NEW FACTS RAISED CONCERNS ABOUT USE OF 
MSCs AS AN ANTICANCER THERAPY  
 MSCs have the capability to home to the tumor site after 
systemic delivery which provokes great interest and signifi-
cant progress in the anticancer research. Despite extensive 
investigations over the last few years, the influence of MSCs 
on tumor progression remains unclear because of contradic-
tory results. There are studies reporting promotions of tumor 
progression and metastasis, while others record suppression 
of tumor growth [119]. Numerous animal model studies have 
documented the therapeutic potential of MSCs and their 
safety and efficacy in vivo. But the anti-cancer properties of 
MSCs in humans are controversial because of still incom-
plete and limited human studies performed on small number 
of patients. The proposed use of MSCs in cancer therapies 
provoke strong disagreement in scientific community, due to 
opposite results for MSC promotion of tumor vasculariza-
tion, promotion of cancer progression and the invasive ten-
dency of tumors previously reported [28, 120-122]. In this 
contest, Li et al., 2011, inform about the dual role of human 
MSCs in tumor cell growth in vitro and in vivo. It was found 
that in vitro human MSCs inhibited the proliferation of A549 
(lung cancer) and Eca-109 (esophageal cancer) cell lines and 
caused G1 phase cell cycle arrest and apoptosis. On the other 
hand, human MSCs were also found to increase tumor for-
mation and growth in experiments in vivo [123]. 
 Tumormodulatory effects of MSCs are under considera-
tion also, because there are studies in animal models show-
ing the ability of MSCs to home to sites of tumor and sup-
press or stimulate tumor growth via antiapoptotic effect, tu-
mor progression, metastasis, and drug-resistance of cancer 
cells [124-128]. For illustration, in some experiments inhibi-
tion of primary tumor growth was observed after co-injection 
of MSCs with tumor cells in models of Lewis lung carci-
noma and B16 melanoma [129], whereas the co-culture of 
MSCs with breast cancer cells improved tumor cell prolifera-
tion [130]. In part, the role of IL-6 secreted by MSCs in 
promoting multiple myeloma proliferation begins to clarify 
with molecular studies that give suggestions about the under-
lying mechanisms [131]. In the study of Serakinci et al.,  
in vivo assays were performed to investigate if externally 
administered hMSCs would engraft at the tumor sites and 
interact with the cancer cells [132]. Karnoub et al. [27], in 
the past few years, also demonstrated integration of MSCs 
into breast cancer stroma and increase of cancer cell metasta-
sis by MSC-secreted chemokine CCL5-dependent signaling. 
Additionally, the interaction between the immune cells and 
MSCs needs to be studied in vivo because MSCs transplants 
in animal models proved beneficial for some diseases, but 
had no effect in others. Thus, consideration and understand-
ing of the inter- and intra-relationships between MSCs and 
cancer is essential for the improvement and progress of anti-
cancer therapies and clinical exploitation of MSCs.  
 Another tumor enhancing property of MSCs is their abil-
ity to suppress the immune system [133]. While this immu-
nosuppressive characteristic of MSCs is a desired property 
for patients with immune disorders, this ambiguous nature of 
MSCs may cause harm to patients with cancer, as a sup-
pressed immune system may encourage tumor growth.  
 In the case of peritoneal cancers, MSCs from bone origin 
have been reported to locate around the tumor and in the 
ascitic fluid and, at the same time, became unable to differ-
entiate in different cell lineages (loos of multipotent ability). 
These cells are defined as being carcinoma-associated (CA-
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MSCs) and possess some characteristic markers of Carci-
noma-Associated Fibroblasts (CAFs) [134, 135]. Tumor-
stroma interactions are considered a fundamental necessity 
for tumor development and progression. Interplay between 
tumor and non-malignant host cells (e.g., stromal cells, im-
mune cells, activated endothelium) has also been described 
[136]. MSCs can be used in investigations of tumor micro-
environment for anticancer drug development as is presented 
in the patent published in 2012 by Banerjee et al. [137]. The 
invention briefly presents an extracellular matrix bioscaf-
folds that includes CAF-like cells and tumor associated 
macrophages supporting tumor growth and formation, which 
can be used for the development of known or novel antican-
cer drugs. The CAF-like cells of the present invention may 
be differentiated from pluripotent HBMC, and such cells 
may include MSCs that are differentiated to exhibit one or 
more of the phenotypes. One method for MSC differentiation 
is by culturing the cells in tumor conditioned medium for 
about 1 to 30 days. 
 The invention of Derr et al., 2013 [138], provides new 
methods (signals as level of gene expression is) for classify-
ing candidates for treatment with cancer associated mesen-
chymal cells, tumor initiating cancer cells, or cancer stem 
cell inhibitor treatment. In one embodiment, the cancer is 
characterized as including and enriched with cancer associ-
ated mesenchymal cells and the invention features adminis-
tering an agent that inhibits or kills cancer associated mesen-
chymal cells or cancer stem cells based on the characterized 
gene expression profile. 
 There are recent findings that MSCs can be involved in 
the drug resistance development due to the release of various 
factors in the neighborhood of tumors [139-143]. Kurtova  
et al. reported that MSCs protect chronic lymphocytic leu-
kaemic cells from apoptosis induced by fludarabine, dex-
amethosone, and cyclophosphamide [125]. In Fig. (2), a 
summary of the MSCs involvements in cancer development 
by above mentioned indirect effects is given.  
Table 3. Different Roles of MSCs used as Drug Delivery Vehicles for Anticancer Therapy. 
Different Roles of MSCs in Anticancer Drug Deliv-
ery Systems 
Result Cited References 
MSCs stimulate DCs to produce IFN  Promotes tumor suppression [75, 76] 
Incubation of isolated MSCs with Toll-like receptor 
ligand (TLR) 
Avoid troubleshoots occurring in stem cell therapy in adult patients [82] 
Use of engineered MSC as a vehicle to deliver secreted 
tissue necrosis factor-RGD4C fusion polypeptides  
Reduce side effects of TNF [84] 
Use of genetically modified MSCs for monitoring the 
distribution in the recipient 
Detection by bioluminescence, fluorescence, MRI, or PET scanning [84] 
Generating and expanding the human embryonic-
mesenchymal stem cells (hES-MSCs) 
A kit comprises hES-MSCs as cell delivery carriers can be provided [86] 
Umbilical Cord Blood-Derived Mesenchymal Stem 
Cells (UCB-MSCs) 
Transfer a therapeutic agent inhibiting brain tumor cells growth or a 
therapeutic gene (an antitumor gene, a prodrug converting enzyme gene, 
or oncolytic virus) 
[87] 
Labeling with magnetic nanoparticles Target delivery of anticancer agents [88] 
Introducing a gene coding green fluorescent protein 
(GFP) into UCB-MSCs 
Diagnose, prevent, and treat diseases related to cells expressing IL-8 or 
GRO- or brain tumors 
[89] 
Cancer vaccines Target tumors and make differences between neoplastic and healty cells [90, 91] 
Use of intra-and extracellular components of stem cells 
A rich source of biomolecules associated with epigenetic reprogram-
ming, or alteration of the malignant nature of the cancer cells 
[93] 
Extract extracellular medium of a stem cell  
(OmniCytes) 
Prepare a conditioned extracellular medium as an apoptosis-modulating 
cell-free composition 
[92] 
MSCs particles Particles (vesicle or exosome) possess biological properties of a MSC [95] 
Expressing a suicide gene  
High selective anticancer effects (conversion of a prodrug to an antican-
cer agent at the cancer site) 
[98-102] 
Micro carriers for protein delivery Deliver large quantities of the therapeutic agent for extended periods of time [104, 105] 
Secreting TRAIL Inducing apoptosis and inhibition of tumor growth [108, 114-116] 
Delivering of oncolytic viruses Induction of apoptosis [117] 
Engineered MSCs for secretion of antibody-like molecules Can lead to elimination of early cancer cell metastasis [118] 
Perspectives in Engineered Mesenchymal Stem Recent Patents on Anti-Cancer Drug Discovery, 2016, Vol. 11, No. 1    107
 With a number of target therapeutics currently under de-
velopment as anticancer therapy, not only cancer cells, but 
also cells from the microenvironment (endothelial cells or 
MSCs) are targeted. This therapeutic approach may have 
many adverse effects associated with the elimination of cells 
not involved in cancer progression or in chemoresistance. 
There is still no confirmation of this hypothesis, and investi-
gations are still in progress as many authors have described 
cells from the microenvironment which exhibit several dif-
ferences with their parent cells. In one study [28]. Isolated 
primary glioblastoma multiforme (GBM) cells are co-cultured 
with MSCs and their characteristics are analyzed with co-
transplantation assays. The experiment demonstrates that 
UCB-MSCs inhibit proliferative activity of GBM, whereas at 
the same time, adipose tissue-derived MSCs (AT-MSCs) 
support GBM proliferation. According to this study, the 
sources of MSCs and associated pathologies are very impor-
tant for their clinical application. Parental cells (macro-
phages, neutrophils or MSCs) primarily possess anticancer 
attributes. Different MSC classes show tumor cell cytotoxic-
ity, while others do not, which is in consensus with previous 
reports that proposed contradictory effects of MSCs on tu-
mor cell proliferation [36, 59, 144]. There is a number of 
studies that employed cancer cell cultures and a part of them 
reported intensifying of cancer cell proliferation when MSCs 
are added [120, 121], and some reported recordable MSCs 
anticancer activity [23, 33, 34, 63, 72, 144, 145]. Conven-
tional anticancer drug screening in vitro is typically per-
formed in the absence of additional cells from the tumor mi-
croenvironment, which can alter obtained results about anti-
tumor activity in vivo. Preclinical drug testing unaccompa-
nied with experiments closely connected to tumor microenvi-
ronment interactions may be a relevant explanation about the 
divergence in preclinical and clinical drug efficacy in can-
cers [146].  
CURRENT AND FUTURE RESEARCH AND DEVEL-
OPMENTS 
 An important topic in anticancer therapy are serious ad-
verse effects of anticancer drugs on healthy tissues and in 
some cases dose reduction, delay of therapy or even discon-
tinuance is needed. Toxicity for healthy tissues can be nota-
bly reduced by using a drug delivery system which selec-
tively targets cancer cells. As a consequence, a need for 
more targeted anticancer therapies is obvious. A lot of re-
searchers are in agreement that therapy based on targeted 
delivery is a promising tool, particularly in cancer treatments 
[147]. Targeted drug-delivery systems (e.g., liposomes, 
nano-particles) have often been proposed in an effort to re-
duce the side effects of toxic drugs and improve the efficacy 
of treating malignant diseases. This “nano-carriers” as pas-
sive-targeted drug-loaded vehicles are still the predominant 
delivery systems used for cancer therapy. However, these 
systems have limitations in their use by tumor vasculariza-
tion and permeability that are largely dependent on the stage 
of malignancy and tumor type [148]. 
 Most of artificial/passive drug vehicle systems used caused 
numerous problems, such as immune reactions and accumu-
lation also in normal tissues, so MSCs, as cell-based active 
targeting vehicles, may be a possible solution. When drug 
resistance is an issue, MSCs can also be of importance be-
cause of the possibility to deliver more than one anticancer 
agent at the same time.  
Fig. (2). Involvement of mesenchymal stem cells in cancer development by indirect effects. 
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 One very unique and interesting approach is a novel de-
livery platform based on nanoghosts (NGs). NGs are pro-
duced from the whole intact cell membranes of MSCs. MSC-
NGs are manufactured in a reproducible process by isolating 
intact MSC cell membranes (ghost cells) which are homoge-
nized into nanosized vesicles (nanoghosts) while entrapping 
a therapeutic of choice in the inside. The MSC-NGs retained 
MSC-specific in vitro and in vivo tumor targeting capabili-
ties, hypoimmunogenicity and ability to target many kinds of 
cancers at different developmental stages. MSC-NGs can be 
made in different sizes and loaded with a variety of therapeu-
tics, not only cell-made ones. In the study reported by Tole-
dano Furman et al., 2013 [149], the efficacy of MSC-derived 
NGs against cancer was demonstrated using a prostate can-
cer model and by encapsulating TRAIL (the biologic model 
drug) insight. 
 Further investigations of MSCs recourses and complete 
understanding of specific combinations of factors controlling 
their tumor-specific migration and persistence will help these 
new technologies to be translated to clinical setting. Expand-
ing the current knowledge about properties and mechanisms 
of action of MSCs associated with cancer in the ways men-
tioned previously, would benefit to the development of po-
tential diagnostic, prognostic and therapeutic agents. Cur-
rently, there are about 690 clinical studies recorded by U.S. 
National Institutes of Health, concerning different uses of 
MSCs in anticancer therapy. Some of these studies are re-
cently completed, and some of them are still in initial stages 
of recruiting patients. Nobody can predict how many of the 
proposed compositions will be registered and approved as 
anticancer drugs. Inconsistent results obtained in studies 
about MSCs themselves and on tumor cell proliferation are 
still of concern and should be deeply analyzed before using 
an MSC-based anticancer therapy. Using MSCs cannot en-
tirely replace the conventional anticancer therapy, but can be 
a pathway for making a personalized therapy suitable for 
different cancer types. 
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